{
    "medicine_id": "2a74d4f70ca80e3f28ced3a4595fab3362a9ef82",
    "platform_id": "DB11653",
    "metadata": {
        "name": "Vyleesi 1 75 mg 0 3mL Injection",
        "composition": "1 75 mg 0 3mL Bremelanotide",
        "clinical_particulars": {
            "therapeutic_indications": "Bremelanotide is indicated to treat premenopausal women with hypoactive sexual desire disorder that is not due to a medical or psychiatric condition problems with the relationship or the effects of a medication or drug L9635",
            "contraindications": {
                "disease": "Currently there are no reports of overdoses of bremelanotide L9635 Patients taking higher doses are more likely to experience nausea focal hyperpigmentation and increases in blood pressure L9635 In the event of an overdose supportive measures should be used to address the associated symptoms L9635",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Bremelanotide is a melanocortin receptor agonist injected 45 minutes before anticipated sexual activity L9635 Agonism of the melanocortin receptor MC1R also leads to increased melanin expression L9635 Patients taking bremelanotide may also experience nausea headache and vomiting L9635",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00704",
                        "description": "The serum concentration of Naltrexone can be decreased when it is combined with Bremelanotide"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}